Prostate Cancer Therapy Respones: An ELISA study on the Role of MMP9

Abstract

Numerous studies have evaluated the association between the matrix metalloproteinase 9 (MMP-9) and prostate cancer (PCA) risk. However, these studies have yielded conflicting results. As one of the most widely investigated matrix metalloproteinases (MMPs), MMP-9 is a significant protease which plays vital roles in many biological processes. MMP-9 can cleave many extracellular matrix (ECM) proteins to regulate ECM remodelling. It can also cleave many plasma surface proteins to release them from the cell surface. MMP-9 has been widely found to relate to the pathology of cancers, including but not limited to invasion, metastasis and angiogenesis. Some recent research evaluated the value of MMP-9 as biomarkers to various specific cancers. Besides, recent research of MMP-9 biosensors discovered various novel MMP-9 biosensors to detect this enzyme. In our findings provide further evidence that the expression of MMP-9 contribute to PCA risk. MMP-9 protein overexpression was found in prostate cancers, low expression in any of the normal tissues or in benign prostatic tissue. MMP-9 is potentially an important prostate tumor marker. Such research could ultimately contribute to more personalized and effective treatment strategies for patients with prostate cancer.